Cogent Biosciences Inc Aktie News

Fairmount Funds Management LLC sold 3,500,000 shares indirectly on Jan. 22, 2026, at $36.40 per share, generating a transaction value of approximately $127.4 million. This sale represented 38.87% of the reporting entities' total indirect holdings and reduced indirect ownership from 9,003,418 to 5,503,418 shares.

-   Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo.

-  PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib  -  Cogent is expected to initiate the RTOR process immediately; completion of the PEAK NDA submission expected in April 2026 WA...

Cogent Biosciences, Inc. (COGT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

WALTHAM, Mass. and BOULDER, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2026 milestones ahead of its presentation at J.P. Morgan's 44th annual healthcare conference. “2025 was marked by exceptional progress at Cogent Biosc...

According to a Form 4, one Cogent Biosciences insider sold 65,000 shares of the biotech on Dec. 26 for a total value of $2.52 million. This sale represented 37.27% of Evan Kearns's direct holdings, as reported, reducing direct ownership to 109,398 shares.

WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 202...

The biotech's chief legal and financial officers were among four executives who sold shares on the same day.